Novel marker and possible therapeutic target for cardiovascular calcification identified

Cardiovascular calcification (deposits of minerals in heart valves and blood vessels) is a primary contributor to heart disease, the leading cause of death among both men and women in the United States according the Centers for Disease Control and Prevention (CDC).

"Unfortunately, there currently is no medical treatment for cardiovascular , which can lead to acute cardiovascular events, such as myocardial infarction and stroke, as well as heart failure," says Elena Aikawa, MD, PhD, Director of the Vascular Biology Program at the Center for Interdisciplinary Cardiovascular Sciences at Brigham and Women's Hospital (BWH) and Associate Professor of Medicine at Harvard Medical School. "We haven not found a way to reverse or slow this disease process, which is associated with aging and common chronic conditions like atherosclerosis, diabetes, and kidney disease."

Led by Dr. Aikawa, a team of researchers at BWH and Kowa Company, Ltd., a Japanese pharmaceutical company, has discovered certain proteins in osteoclasts, a precursor to bone, that may be used in helping to destroy cardiovascular calcification by dissolving mineral deposits. The research, described in the March 2014 issue of Arteriosclerosis, Thrombosis, and Vascular Biology, suggests a potential therapeutic avenue for patients with cardiovascular calcification.

Mature osteoclasts are not typically found in the . Using unbiased global proteomics (study of proteins), the researchers were able to examine osteoclast-like cells in the vasculature to determine which proteins induced osteoclast formation. They identified more than 100 proteins associated with osteoclast development. Follow-up study validated six candidate proteins, which serve as targets for possible medications that may help promote osteoclast development in the vasculature.

"To advance this research, we need to further understand why osteoclasts are not prevalent in the vaculature, despite active calcification of the heart valves and , and determine the difference between calcification in vasculature compared with calcification in bone," said Dr. Aikawa. "Then, we may examine ways to form osteoclasts in the vasculature."

More information: atvb.ahajournals.org/content/34/3/626.abstract

add to favorites email to friend print save as pdf

Related Stories

New blood test detects potentially deadly calcium deposits

Sep 06, 2012

A new test could help identify and treat individuals at risk of developing potentially deadly calcium deposits in their tissues and blood vessels, according to a study appearing in an upcoming issue of the Journal of the Am ...

A new treatment for kidney disease-associated heart failure?

Jan 09, 2013

Chronic kidney disease (CKD) patients frequently suffer from mineral bone disorder, which causes vascular calcification and, eventually, chronic heart failure. Similar to patients with CKD, mice with low levels of the protein ...

Recommended for you

Vitamin D does not stop heart attack or stroke

19 hours ago

(Medical Xpress)—Taking vitamin D tablets cannot ward off heart attacks or stroke according to a new study from researchers at the University of East Anglia (UEA) published in the American Journal of Cl ...

New guidance on antithrombotic use in AF patients with ACS

20 hours ago

A new European joint consensus document on the use of antithrombotic drugs, including the non-vitamin K antagonist oral anticoagulants (NOACs), in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome ...

USPSTF recommends counseling for adults at risk for CVD

Aug 26, 2014

(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends offering or referring overweight and obese adults with cardiovascular disease risk factors to intensive behavioral counseling. These ...

User comments